Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma. (PubMed, Br J Haematol) - Sep 28, 2026 - "Brentuximab vedotin (BV)-doxorubicin, vinblastine and dacarbazine (AVD) and nivolumab (N)-AVD have transformed the frontline treatment of advanced-stage Hodgkin lymphoma (HL), yet real-world comparative data remain limited. Survival outcomes were consistent in a 1:1 propensity score-matched cohort. These real-world data demonstrate comparable survival between regimens, with numerically improved PFS supporting N-AVD as a frontline standard for advanced-stage HL; however, higher rates of neutropenia and infections warrant careful monitoring and consideration of growth factor prophylaxis."
Journal • Real-world evidence • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Oncology • Pain • Pediatrics
|
|
Amy Ayers; Ashleigh Hawk; B Paige DePriest; Branko Cuglievan; Catherine Diefenbach; Chalothorn Wannaphut; Efrat Luttwak; Elif Yilmaz; Hayley Flanagan; Hiba Narvel; Hunter Cochran; Jamie Flerlage; Jonathan D Bender; Julia Fadul; Justin Kahla; Karan L Chohan; Katherine Tobon; Kris M Mahadeo; Lei Feng; Leidy Isenalumhe; Mallorie B Heneghan; Maya Rosenberg; Mehdi Hamadani; Miriam B Garcia; Nancy Bartlett; Olivia Tran; Pallawi Torka; Patricia Faulkenberry; Peter Riedell; Radhamani Kannaiyan; Robin E Norris; Sairah Ahmed; Salmaan Mubeen; Samanta Catueno; Seo-Hyun Kim; Sharon Castellino; Sunita Nathan; Supreet Kaur; Yun Kyoung Tiger
|